Novyra Pharmachem Ltd
Novyra Pharmachem Ltd (NOVYRA) last reported results for the quarter ended Jun 2026, with sales of ₹1.73 crore and net profit of ₹-0.02 crore. The stock last traded at ₹8.71, a market capitalisation of ₹5.51 crore. Over the past 52 weeks the stock has ranged between ₹6.47 and ₹16.6. Figures are as of 9 Oct 2026 and are not real time.
Novyra Pharmachem Ltd share price and key metrics
- Current price
- ₹8.71
- Market cap
- ₹5.51 cr
- Book value
- ₹0.98
- ROE
- -162%
- ROCE
- -162%
- Dividend yield
- 0.00%
- 52w high / low
- 16.6/6.47
Metrics as of 9 Oct 2026. Not real time.
Track Novyra Pharmachem Ltd
Cruxal reads every Novyra Pharmachem Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Novyra Pharmachem Ltd growth and returns
- 10 Years
- -21%
- 5 Years
- -8%
- 3 Years
- -13%
- TTM
- %
- 10 Years
- %
- 5 Years
- %
- 3 Years
- %
- TTM
- -7586%
- 10 Years
- %
- 5 Years
- 23%
- 3 Years
- 21%
- 1 Year
- 41%
- 10 Years
- -10%
- 5 Years
- -20%
- 3 Years
- -37%
- Last Year
- -162%
Novyra Pharmachem Ltd quarterly results
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0.1 | 1.73 |
| Expenses | 0 | 0.01 | 0.07 | 0.03 | 0 | 0.02 | 5.43 | 1.75 |
| Operating profit | 0 | -0.01 | -0.07 | -0.03 | 0 | -0.02 | -5.33 | -0.02 |
| OPM % | — | — | — | — | — | — | -5,330.00% | -1.16% |
| Other income | 0 | 0 | 0.05 | 0.03 | 0.02 | 0 | 0 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0.03 | 0.01 | 0.01 | 0.01 | 0.01 | 0 |
| Profit before tax | 0 | -0.01 | -0.05 | -0.01 | 0.01 | -0.03 | -5.34 | -0.02 |
| Tax % | — | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net profit | 0 | -0.01 | -0.05 | -0.01 | 0.01 | -0.03 | -5.34 | -0.02 |
| EPS (₹) | 0.00 | -0.02 | -0.08 | -0.02 | 0.02 | -0.05 | -8.44 | -0.03 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Novyra Pharmachem Ltd annual results
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1.5 | 1.73 | 1.72 | 0.15 | 0.15 | 0.15 | 0.15 | 0 | 0 | 0.1 | 1.83 |
| Operating profit | 0.09 | 0 | -0.1 | 0 | 0.06 | -0.02 | 0.04 | -0.14 | -0.08 | -5.4 | -5.37 |
| OPM % | 6.00% | 0.00% | -5.81% | 0.00% | 40.00% | -13.33% | 26.67% | — | — | -5,400.00% | -293.44% |
| Net profit | 0.02 | -0.04 | -0.13 | -0.02 | 0.08 | 0 | 0.01 | -0.16 | -0.06 | -5.37 | -5.38 |
| EPS (₹) | 0.03 | -0.06 | -0.21 | -0.03 | 0.13 | 0.00 | 0.02 | -0.25 | -0.09 | -8.48 | -8.50 |
TTM is the trailing twelve months to the most recent quarter.
Novyra Pharmachem Ltd balance sheet
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity capital | 6.20 | 6.20 | 6.20 | 6.20 | 6.20 | 6.20 | 6.20 | 6.20 | 6.33 | 6.33 |
| Reserves | -0.02 | -0.06 | -0.19 | -0.20 | -0.13 | -0.12 | -0.11 | -0.27 | -0.33 | -5.71 |
| Borrowings | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other liabilities | 0.42 | 0.38 | 0.18 | 0.08 | 0.15 | 0.13 | 0.16 | 0.19 | 0.18 | 0.87 |
| Total liabilities | 6.60 | 6.52 | 6.19 | 6.08 | 6.22 | 6.21 | 6.25 | 6.12 | 6.18 | 1.49 |
| Fixed assets | 5.01 | 4.98 | 5.03 | 5.13 | 5.11 | 5.10 | 5.08 | 5.06 | 4.93 | 0.74 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other assets | 1.59 | 1.54 | 1.16 | 0.95 | 1.11 | 1.11 | 1.17 | 1.06 | 1.25 | 0.75 |
| Total assets | 6.60 | 6.52 | 6.19 | 6.08 | 6.22 | 6.21 | 6.25 | 6.12 | 6.18 | 1.49 |
As reported by the company. Total assets equal total liabilities by construction.
Novyra Pharmachem Ltd cash flow
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -0.27 | -0.04 | -0.09 | 0.01 | -0.02 | -0.06 | 0.14 | -0.14 | -0.28 | -3.79 |
| Cash from investing | -0.02 | 0.00 | -0.07 | -0.12 | 0.05 | 0.03 | 0.01 | 0.00 | 0.18 | 3.85 |
| Cash from financing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.28 | -0.15 |
| Net cash flow | -0.28 | -0.04 | -0.16 | -0.11 | 0.03 | -0.03 | 0.14 | -0.14 | 0.18 | -0.09 |
| Free cash flow | -0.38 | -0.04 | -0.16 | -0.11 | -0.02 | -0.07 | 0.14 | -0.14 | -0.18 | -0.07 |
| CFO / operating profit | -267% | — | 90% | — | -17% | 300% | 400% | 100% | 350% | 70% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Novyra Pharmachem Ltd operating ratios
| Per year | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % | 0.81% | -0.49% | -1.98% | -0.33% | 1.49% | 0.00% | 0.49% | -2.66% | -1.01% | -162.24% |
| Debtor days | 80.30 | 50.64 | 31.83 | 170.33 | 146.00 | 194.67 | 340.67 | — | — | 36.50 |
| Inventory days | 16.85 | 64.41 | 0.00 | — | — | — | — | — | — | — |
| Days payable | 168.46 | 257.65 | — | — | — | — | — | — | — | — |
| Cash conversion cycle | -71.32 | -142.60 | 31.83 | 170.33 | 146.00 | 194.67 | 340.67 | — | — | 36.50 |
| Working capital days | -17.03 | -8.44 | -6.37 | -48.67 | 121.67 | 146.00 | 219.00 | — | — | -1,095.00 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Novyra Pharmachem Ltd shareholding pattern
Promoters held 23.15% at Jun 2026, broadly unchanged since Jun 2025.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 23.15% | 23.15% | 23.15% | 23.15% | 23.15% | 23.15% | 23.15% | 23.15% |
| Public | 76.84% | 76.84% | 76.85% | 76.85% | 76.85% | 76.85% | 76.86% | 76.86% |
| No. of shareholders | 27,891 | 27,889 | 27,877 | 27,877 | 27,633 | 27,588 | 27,577 | 27,587 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Novyra Pharmachem Ltd corporate filings
- Closure of Trading WindowInsider Trading / SASTlow impact
- Novyra Pharmachem Ltd: Intimation under Regulation 30Company Updatelow impact
Cruxal's analysis: Novyra Pharmachem Ltd has filed a routine intimation under Regulation 30 of the SEBI…
Read the full analysis - Bansisons Tea Industries Ltd: Routine Regulation 30 DisclosureCompany Updatelow impact
Cruxal's analysis: Bansisons Tea Industries Ltd has filed a routine Regulation 30 disclosure. The company…
Read the full analysis - Novyra Pharmachem Limited reports Q1 FY2027 financial results with net loss of 1.99 lakhBoard Meetingmedium impact
Cruxal's analysis: Novyra Pharmachem Limited reported a net loss of 1.99 lakh for the quarter ended June 30…
Read the full analysis - Novyra Pharmachem Limited schedules Board Meeting for 14th August 2026 to approve Q1 FY27 financial resultsBoard Meetinglow impact
Cruxal's analysis: Novyra Pharmachem Limited has formally intimated the BSE regarding a Board of Directors…
Read the full analysis - Bansisons Tea Industries Ltd announces change of company websiteCompany Updatelow impact
Cruxal's analysis: Bansisons Tea Industries Ltd (BSE: 519353) has informed the exchange about a change in…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.